Novimmune’s successor company receives milestone payment from Takeda

Light Chain Bioscience, a company developing bispecific antibodies with a pipeline focused in immuno-oncology, announced that it has achieved a milestone and received a payment under its research and collaboration agreement with Takeda Pharmaceutical Company Limited. The collaboration aims at developing bispecific antibodies with Factor VIII mimetic activity for the treatment of hemophilia A patients.

“We are extremely excited to have reached this important milestone in our collaborative program. The successful identification and optimization of new therapeutic candidates adds to the validation of our bispecific antibody discovery expertise. It has been a very fruitful collaboration and a unique learning experience for us to work with Takeda to develop a bispecific approach for an indication such as hemophilia A,” said Nicolas Fischer, Light Chain Bioscience’s Chief Executive Officer.

Following the successful divestment of EmaCo AG, a newly established company owning emapalumab and related assets to Sobi on 18 July 2019, NovImmune underwent major rebranding activities. NovImmune SA continues the legacy of 20+ years of antibody expertise and focusses on its bispecific technology and associated programs and rebranded as: «Light Chain Bioscience – A brand of Novimmune SA». CEO Nicolas Fischer works for Novimmune since 2002 and headed the research department between 2010 and 2019.